| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | 72.8 | ¤871,596 | US |
| JNJ | Johnson & Johnson | 62.9 | ¤578,307 | US |
| AZN | AstraZeneca PLC | 65.4 | ¤316,959 | GB |
| MRK | Merck & Co., Inc. | 63.0 | ¤296,588 | US |
| AMGN | Amgen Inc. | 65.4 | ¤189,186 | US |
| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| THC | Tenet Healthcare Corporation | 66.0 | ¤17,097 | US |
| DGX | Quest Diagnostics Incorporated | 54.3 | ¤21,332 | US |
| STE | STERIS plc | 59.5 | ¤22,050 | IE |
| DXCM | DexCom, Inc. | 74.6 | ¤24,227 | US |
| UTHR | United Therapeutics Corporation | 71.2 | ¤25,356 | US |
| Symbol | Name | Grade | Times* | Country |
|---|---|---|---|---|
| AMGN | Amgen Inc. | 65.4 | 32 | US |
| LLY | Eli Lilly and Company | 72.8 | 27 | US |
| PFE | Pfizer Inc. | 51.3 | 25 | US |
| DGX | Quest Diagnostics Incorporated | 54.3 | 23 | US |
| ZTS | Zoetis, Inc. Class A | 63.0 | 23 | US |
| BMY | Bristol-Myers Squibb Company | 62.3 | 22 | US |
| JNJ | Johnson & Johnson | 62.9 | 22 | US |
| RMD | ResMed Inc. | 72.4 | 20 | US |
| GILD | Gilead Sciences, Inc. | 71.0 | 19 | US |
| UTHR | United Therapeutics Corporation | 71.2 | 18 | US |
| Average Market Cap | ¤134,052 |
| Median Market Cap | ¤51,124 |
| Avg. 3 Mo. Dollar Vol. | ¤663,246,485 |
| Avg. 3 Mo. Trading Vol. | 4,716,548 |
| Last Rebalance Date | 03/23/2026 |
| Companies Replaced | 7 |
| Biggest Sector Increase | Health Care |
| Biggest Sector Decrease | Health Care |
| Trailing P/E Ratio (12 Mo.) | 24.7 |
| Forward P/E Ratio (12 Mo.) | 19.8 |
| Price/Book Ratio | 5.6 |
| Avg. Revenue Chg. - 3 Yr | 21.8% |
| Avg. Op. Income Chg. - 3 Yr. | 37.7% |
| Avg. EPS Growth - 3 Yr. | 13.8% |
| Avg. EPS Growth - 1 Yr. | 14.3% |
| Avg. Operating Margin | 23.5% |
| Avg. LT Debt to Total Capital | 42.2% |
| Avg. Return on Equity | 22.5% |
| Dividend Yield | 0.6% |
| US Health Care Index | 61.51 |
| United States Of America | 90.0% |
| Switzerland | 3.33% |
| United Kingdom | 3.33% |
| Ireland | 3.33% |
